SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJudges Scientific Regulatory News (JDG)

Share Price Information for Judges Scientific (JDG)

Share Price is delayed by 15 minutes
Get Live Data
4,450.00    0.00 (0.00%)
Bid:
4,400.00
Ask:
4,580.00
Spread: 180.00 (4.091%)
Market Cap: £296.40m
JDG Live PriceLast checked at - London Stock Exchange

Intraday Judges Scientific Share Chart

Acquisition

19 Mar 2010 07:00

RNS Number : 8335I
Judges Scientific PLC
19 March 2010
 



19 March 2010

 

JUDGES SCIENTIFIC plc

("Judges Scientific", "Judges" or the "Company")

 

ACQUISITION OF SIRCAL INSTRUMENTS (UK) LIMITED

 

Judges Scientific, the parent company of a group that specialises in the design, manufacture and sale of scientific instruments, announces that its wholly-owned subsidiary, Fire Testing Technology Limited ("FTT"), has today completed the acquisition of the entire issued share capital of Sircal Instruments (UK) Limited ("Sircal") for a consideration of £1 million, payable in cash. An additional payment will be made to reflect the working capital available at completion in excess of the ongoing requirements of the business. Such payment is expected by Judges to be more than covered by the cash inherited at completion.

 

Sircal designs, manufactures and distributes rare gas purifiers for use in metals analysis utilising the Arc Spark spectrometry technique. This technique provides qualitative and quantitative analysis of a metallic sample. The process does not require complicated sample preparation and is widely used in the metals industry. When accurate measurements are required, the process must be carried out in an environment free from the type of contaminants that would affect the performance of the metal; the test is therefore conducted in an atmosphere of rare gas (usually argon) that is itself sufficiently free from contamination.  The function of the purifier is to achieve the required rare gas purity.

 

The principal markets for Arc Spark spectrometry relate to the production of speciality steel, cast iron, aluminium and other non-ferrous metals. These are the markets served by Sircal, directly or through OEM customers who manufacture spectrometers. In contrast to the majority of Judges' existing operations, Sircal is largely reliant on the private sector. The vast majority of Sircal's production is exported, as is the case with the other businesses in the Judges group. Judges believes the company to be a clear world leader in the market for purifiers used in metals analysis. Sircal's revenues include a significant element of consumables (approximately 30% in the last financial year).

 

The two vendors were among the founders of Sircal in 1981 and since 2004 have been its only employees. It has been agreed that they will assist Judges during a three-month transition period while the business is transferred to FTT's premises, where it will be operated by the FTT team. Judges Scientific will not assume responsibility for Sircal's existing premises. The Board of Judges believes that risk is reduced in such an acquisition where the purchaser does not inherit responsibility for staff or premises.

 

Sircal's unaudited accounts for the year ended 30 September 2009 show sales of £785,000 on which the company generated operating profits of £337,000. Net tangible assets at 30 September 2009 amounted to £423,000, including £458,000 of cash and cash equivalents. Sircal's operating profits figure of £337,000 reflects the way the business has been operated historically; the Board of Judges believes that, had the business been owned by the Company during that period, it would have generated a contribution in the order of £270,000. The Board expects the acquisition to be earnings-enhancing in the current year.

 

The Bank of Scotland has made available to Judges a £1 million extension to the £3 million term loan which was arranged in June 2009 to finance the acquisition of Quorum Technologies Limited and to refinance the Company's outstanding borrowings at that time. In addition, a £500,000 overdraft facility continues to be available to the Company.

 

Alex Hambro, Chairman of Judges, commented: "I am delighted that we have purchased another niche instrument business and that we have been able to do so without issuing shares. We regard our level of indebtedness as prudent, Sircal comes without the usual fixed cost commitments and the nature of its customer base will serve to moderate the Group's current bias towards public sector markets. This acquisition should prove earnings-enhancing in the current year, while providing an unusually low level of added risk".

 

Enquiries:

 

David Cicurel, CEO, Judges Scientific: Tel: 01342 323 600

 

Pascal Keane, Shore Capital: Tel: 020 7408 4090

 

Melvyn Marckus, Cardew Group: Tel: 07775 896 491

 

Web sites:

 

Judges Scientific: www.judges.uk.com

 

Sircal: www.sircal.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUWRWRRUAOAAR
Date   Source Headline
11th Jun 20264:34 pmRNSDirector/PDMR Shareholding
1st Jun 20262:24 pmRNSTotal Voting Rights
26th May 20265:18 pmRNSPurchase of Ordinary Shares
20th May 20262:52 pmRNSResult of AGM
11th May 20263:10 pmRNSDirector/PDMR Shareholding
8th May 20265:05 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSNotice of AGM
22nd Apr 202611:53 amRNSConfirmation of Full Year Results
9th Apr 202611:14 amRNSDirector/PDMR Shareholding
2nd Apr 20267:00 amRNSDirector/PDMR Shareholding
31st Mar 20267:00 amRNSUnaudited Preliminary Results
25th Mar 20267:00 amRNSNotice of Investor Presentation
10th Mar 20267:00 amRNSDirector/PDMR Shareholding
9th Feb 20261:49 pmRNSDirector/PDMR Shareholding
2nd Feb 20269:38 amRNSTotal Voting Rights
29th Jan 20263:31 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSGrant of Options
22nd Jan 20267:00 amRNSFull Year Trading Statement and Notice of Results
8th Jan 202611:18 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSBlocklisting Return
22nd Dec 20257:00 amRNSBlocklisting Return
9th Dec 202510:25 amRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSAcquisition of the minority shareholding in GdB
26th Nov 20257:00 amRNSBoard Succession
13th Nov 20255:05 pmRNSDirector/PDMR Shareholding
11th Nov 202512:08 pmRNSDirector/PDMR Shareholding
3rd Nov 20257:00 amRNSTotal Voting Rights
20th Oct 20257:00 amRNSDirector/PDMR Shareholding
8th Oct 202511:43 amRNSDirector/PDMR Shareholding
1st Oct 202512:22 pmRNSTotal Voting Rights
18th Sep 20257:00 amRNSInterim Results
9th Sep 202511:42 amRNSDirector/PDMR Shareholding
21st Aug 20257:00 amRNSNotice of Investor Presentation
6th Aug 20255:46 pmRNSDirector/PDMR Shareholding
1st Aug 20257:00 amRNSTotal Voting Rights
30th Jul 20257:00 amRNSDirector/PDMR Shareholding
25th Jul 202510:07 amRNSDirector/PDMR Shareholding
24th Jul 20254:06 pmRNSDirector/PDMR Shareholding
24th Jul 20257:00 amRNSHalf Year Trading Update
8th Jul 20253:53 pmRNSDirector/PDMR Shareholding
1st Jul 20255:08 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSAppointment of Group Acquisitions Executive
23rd Jun 20257:00 amRNSBlocklisting Return
9th Jun 20251:37 pmRNSDirector/PDMR Shareholding
4th Jun 20255:03 pmRNSPurchase of Ordinary Shares
30th May 202512:06 pmRNSTotal Voting Rights
23rd May 202511:25 amRNSResult of AGM
13th May 20255:18 pmRNSPurchase of Ordinary Shares
8th May 20255:27 pmRNSDirector/PDMR Shareholding
28th Apr 20257:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.